Brief: LianBio Announces Positive Topline Results From Phase 2A Trial Evaluating Infigratinib In Chinese Patients

LianBio

06/06/2023 22:01

June 6 (Reuters) - LianBio  LIAN.O :
    * LIANBIO ANNOUNCES TOPLINE RESULTS FROM PHASE 2A PROOF OF
CONCEPT
TRIAL EVALUATING INFIGRATINIB IN PATIENTS WITH GASTRIC CANCER &
RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION IN CHINA
    * LIANBIO- POSITIVE TOPLINE RESULTS FROM A PHASE 2A PROOF OF
CONCEPT TRIAL EVALUATING INFIGRATINIB IN CHINESE PATIENTS
    * LIANBIO- CHINA NMPA GRANTED BREAKTHROUGH THERAPY
DESIGNATION TO
INFIGRATINIB FOR TREATMENT OF GASTRIC CANCER

Source text for Eikon:  ID:nGNX3WM8TQ 
Further company coverage:  LIAN.O 

 ((Reuters.Briefs@thomsonreuters.com;;))